ClinicalTrials.gg
CompletedNCT00760214Updated Nov 15, 2012Results posted

Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension

A Phase 3 interventional study of Azilsartan medoxomil and Azilsartan medoxomil in Hypertension, sponsored by Takeda. Completed at 72 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-11-15.

Primary conditionEssential HypertensionRegistry: HypertensionReclassifiedWhy we changed it
Registry
Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Essential Hypertension
Why
  1. The study's title name Essential Hypertension, a narrower term within Hypertension.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
885
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing azilsartan medoxomil in Essential Hypertension — none open to participants now, none under way, none of them phase 3. azilsartan medoxomil · Essential Hypertension.

Enrollment
5th of 11
885 · median 837
Started
2008
with 1 other
Phase 3
10 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
11 of 11
Takeda

Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, this one is the 5th largest by enrollment, is one of 2 that started in 2008, is one of 10 in phase 3, and was the 5th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

None of the 11 studies testing azilsartan medoxomil in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →

About azilsartan medoxomil

azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing azilsartan medoxomil in Essential Hypertension as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to ramipril for treating Essential Hypertension.

Read the detailed description

A major component of blood pressure regulation is the renin-angiotensin-aldosterone system, a system of hormone-mediated feedback interactions that results in the relaxation or constriction of blood vessels in response to various stimuli. Angiotensin II, a polypeptide hormone, is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme as part of the renin-angiotensin-aldosterone system. Angiotensin II is the principal pressor agent of the renin-angiotensin-aldosterone system with a myriad of effects on the cardiovascular system and on electrolyte homeostasis. Two receptors for angiotensin II have been identified. Angiotensin II type 1 receptors are located predominantly in vascular smooth muscle, where activation by angiotensin II results in vasoconstriction, hypertrophic proliferation, and inflammation. In contrast, stimulation of angiotensin II type 2 receptors by angiotensin II results in vasodilatation, antiproliferative effects that are opposite from those of angiotensin II type 1 receptor stimulation.

Drugs that modulate the renin-angiotensin-aldosterone system are used commonly worldwide for the treatment of hypertension. Of these, some block the synthesis of angiotensin II by inhibiting angiotensin-converting enzymes, while others inhibit the action of angiotensin II by binding directly to the angiotensin II type 1 receptor (called angiotensin II receptor blockers), thereby causing vasodilatation of blood vessels, resulting in a reduction in blood pressure. The effects of angiotensin II receptor blockers on other conditions in which the renin-angiotensin-aldosterone system plays a significant role, such as congestive heart failure, postmyocardial infarction management and diabetic nephropathy have also been investigated.

Although antihypertensive agents are effective at the appropriate dose, the majority have side effects that limit their use. Angiotensin-converting enzyme inhibitors are commonly associated with cough and more rarely with angioedema. Beta-blockers are associated with fatigue and erectile dysfunction, calcium antagonists with peripheral edema and diuretics with metabolic complications. As a class, angiotensin II receptor blockers generally are considered more tolerable than other classes of hypertensive agents, although there is still a need for compounds with improved tolerability and efficacy for the treatment of hypertension.

TAK-491 (azilsartan medoxomil) is an angiotensin II receptor blocker with high affinity for, and selective antagonistic activity at, the angiotensin II type 1 receptor, and is being developed for clinical use as an antihypertensive agent.

Ramipril is an angiotensin-converting enzyme inhibitor widely prescribed in Europe and Asia for the treatment of mild to moderate essential hypertension.

This study is designed to compare the efficacy and safety/tolerability of azilsartan medoxomil and ramipril for the treatment of hypertension.

Participants in this study will be seen twice during the first month, then once a month for five months. Participants will also be required to fast for 8 hours prior to each visit to the study center. Total duration of study participation is 24-weeks, plus a safety follow up phone call after the study has ended.

03

Conditions studied

  • Hypertension

Keywords

  • Essential Hypertension
  • Hypertension
  • Drug Therapy
  • Blood Pressure, High
  • Vascular Disease
  • Cardiovascular Disease
04

In context

Essential Hypertension Reclassified

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

This study's enrollment of 885 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.

Browse Essential Hypertension studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Compared within Essential Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Essential hypertension (sitting systolic blood pressure between 150 and 180 mm Hg, inclusive).
  2. A female participant of who is sexually active agrees to use adequate from screening throughout the duration of the study, and cannot be pregnant.
  3. Has clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory at Screening or the results are deemed not for inclusion into this study by the investigator.
  4. Is willing to discontinue current antihypertensive medications at Screening Day -21. If the participant is on amlodipine prior to screening, the participant is willing to discontinue this medication at Screening Day -28.

Exclusion criteria

Exclusion Criteria:

  1. Has an systolic blood pressure greater than 180 mmHg or diastolic blood pressure greater than 114 mmHg at Randomization.
  2. Is taking or expected to take an excluded medication including antihypertensive agents, insulin or other agents that alter blood pressure.
  3. Is hypersensitive to angiotensin II receptor blockers and/or angiotensin-converting enzyme inhibitors.
  4. Has a recent history within the last 6 months of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or .
  5. Has cardiac conduction defects (eg, third-degree atrioventricular block, left bundle branch block, sick sinus syndrome, atrial fibrillation or flutter).
  6. Has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease.
  7. Has secondary hypertension of any etiology (eg, renovascular disease, pheochromocytoma, Cushing's syndrome).
  8. Is noncompliant (less than 70% or greater than 130%) with study medication during placebo run-in period.
  9. Has severe renal dysfunction or disease (based on calculated less than 30 mL/min/1.73 m² at Screening).
  10. Has known or suspected unilateral or bilateral renal artery stenosis.
  11. Has a history of drug or alcohol abuse within the past 2 years.
  12. Has a previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. (This criterion does not apply to those participants with basal cell or stage I squamous cell carcinoma of the skin).
  13. Has type 1 or poorly controlled type 2 diabetes mellitus ( greater than 8.0%) or is taking insulin.
  14. Has hyperkalemia as defined by the central laboratory normal reference range at Screening.
  15. Has an upper arm circumference less than 24 cm or greater than 42 cm.
  16. Works night (third) shift (defined as 11 PM to 7 AM).
  17. Has an level at Screening of greater than 2.5 times the , active liver disease, or jaundice.
  18. Is currently participating in another study or has participated in an investigational study within 30 days prior to Screening.
  19. Has any other serious disease or condition at Screening or Randomization that would compromise participant's safety, might affect , or make it difficult to successfully manage and follow the participant according to the protocol.
  20. Has been randomized in a previous azilsartan medoxomil study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
885 participants (actual)

Study arms

  • Experimental
    Azilsartan Medoxomil 40 mg QD

    Drug: Azilsartan medoxomil

  • Experimental
    Azilsartan Medoxomil 80 mg QD

    Drug: Azilsartan medoxomil

  • Active comparator
    Ramipril 10 mg QD

    Drug: Ramipril

Interventions

  • Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 40 mg, tablets, orally, once daily for up to 22 weeks.

    Also known as: TAK-491, Edarbi

  • Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 80 mg, tablets, orally, once daily for up to 22 weeks.

    Also known as: TAK-491, Edarbi

  • Ramipril 2.5 mg, tablets, orally, once daily for two weeks; then increased to 10 mg, tablets, orally, once daily for up to 22 weeks.

    Also known as: Tritace, Ramace, Altace

07

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.

    The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 24 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

    Time frame: Baseline and Week 24.

Secondary outcomes

  1. Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure

    The change in mean trough clinic sitting diastolic blood pressure measured at final visit or week 24 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

    Time frame: Baseline and Week 24.

  2. Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in 24-hour mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 24.

  3. Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in 24-hour mean diastolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 24.

  4. Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

    The change in the 12-hour mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

    Time frame: Baseline and Week 24.

  5. Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

    The change in the 12-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

    Time frame: Baseline and Week 24.

  6. Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 24.

  7. Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 24.

  8. Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 24.

  9. Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 24.

  10. Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in trough mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 24.

  11. Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in trough mean diastolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 24.

08

Results

Posted Apr 19, 2011

Participant flow

Participants enrolled at 122 investigative sites in Bulgaria, Estonia, Finland, Germany, the Netherlands, Poland, Russia, Serbia and Montenegro, Slovakia and Sweden from 24 January 2008 to 21 April 2009.

Participant flow — Overall Study
MilestoneAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDRamipril 10 mg QD
Started295294296
Completed265264255
Not completed303041
Withdrew: Adverse event8912
Withdrew: Protocol violation303
Withdrew: Lost to follow-up001
Withdrew: Withdrawal by subject121413
Withdrew: Lack of efficacy324
Withdrew: Pregnancy001
Withdrew: Physician decision111
Withdrew: Other346

Outcome measures

PrimaryChange From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.

The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 24 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDRamipril 10 mg QD
Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.-20.63 ± 0.946-21.24 ± 0.949-12.22 ± 0.948
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Ramipril 10 mg QD · ANCOVA · p = <.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented. Overall 0.05 level of significance for multiple comparisons controlled using stepwise testing procedure.) · Mean difference (final values): -8.41 · 95% CI -11.04 to -5.78
  • Azilsartan Medoxomil 80 mg QD vs Ramipril 10 mg QD · ANCOVA · p = <.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented. Overall 0.05 level of significance for multiple comparisons controlled using stepwise testing procedure.) · Mean difference (final values): -9.03 · 95% CI -11.66 to -6.39
SecondaryChange From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure

The change in mean trough clinic sitting diastolic blood pressure measured at final visit or week 24 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDRamipril 10 mg QD
Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure-10.18 ± 0.553-10.54 ± 0.556-4.87 ± 0.555
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Ramipril 10 mg QD · ANCOVA · p = <.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -5.31 · 95% CI -6.85 to -3.78
  • Azilsartan Medoxomil 80 mg QD vs Ramipril 10 mg QD · ANCOVA · p = <.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -5.66 · 95% CI -7.21 to -4.12
SecondaryChange From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDRamipril 10 mg QD
Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-12.65 ± 1.006-12.29 ± 0.992-7.83 ± 1.022
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Ramipril 10 mg QD · ANCOVA · p = <.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -4.82 · 95% CI -7.64 to -2.01
  • Azilsartan Medoxomil 80 mg QD vs Ramipril 10 mg QD · ANCOVA · p = 0.002 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -4.47 · 95% CI -7.27 to -1.66
SecondaryChange From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean diastolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDRamipril 10 mg QD
Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-8.03 ± 0.655-8.32 ± 0.646-5.26 ± 0.666
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Ramipril 10 mg QD · ANCOVA · p = 0.003 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -2.77 · 95% CI -4.61 to -0.94
  • Azilsartan Medoxomil 80 mg QD vs Ramipril 10 mg QD · ANCOVA · p = 0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -3.06 · 95% CI -4.89 to -1.24
SecondaryChange From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

The change in the 12-hour mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDRamipril 10 mg QD
Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring-12.06 ± 1.103-11.71 ± 1.087-8.28 ± 1.121
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Ramipril 10 mg QD · ANCOVA · p = 0.017 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -3.77 · 95% CI -6.87 to -0.68
  • Azilsartan Medoxomil 80 mg QD vs Ramipril 10 mg QD · ANCOVA · p = 0.029 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -3.43 · 95% CI -6.50 to -0.36
SecondaryChange From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

The change in the 12-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDRamipril 10 mg QD
Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring-7.71 ± 0.743-8.07 ± 0.732-5.65 ± 0.755
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Ramipril 10 mg QD · ANCOVA · p = 0.052 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -2.06 · 95% CI -4.15 to 0.02
  • Azilsartan Medoxomil 80 mg QD vs Ramipril 10 mg QD · ANCOVA · p = 0.022 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -2.42 · 95% CI -4.49 to -0.35
SecondaryChange From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDRamipril 10 mg QD
Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-12.61 ± 1.047-12.35 ± 1.032-8.08 ± 1.064
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Ramipril 10 mg QD · ANCOVA · p = 0.003 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -4.53 · 95% CI -7.46 to -1.59
  • Azilsartan Medoxomil 80 mg QD vs Ramipril 10 mg QD · ANCOVA · p = 0.004 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -4.26 · 95% CI -7.18 to -1.35
SecondaryChange From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDRamipril 10 mg QD
Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-8.19 ± 0.700-8.53 ± 0.689-5.55 ± 0.711
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Ramipril 10 mg QD · ANCOVA · p = 0.008 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -2.64 · 95% CI -4.60 to -0.68
  • Azilsartan Medoxomil 80 mg QD vs Ramipril 10 mg QD · ANCOVA · p = 0.003 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -2.98 · 95% CI -4.93 to -1.04
SecondaryChange From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDRamipril 10 mg QD
Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-12.82 ± 1.135-12.69 ± 1.115-6.87 ± 1.147
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Ramipril 10 mg QD · ANCOVA · p = <.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -5.95 · 95% CI -9.12 to -2.77
  • Azilsartan Medoxomil 80 mg QD vs Ramipril 10 mg QD · ANCOVA · p = <.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -5.82 · 95% CI -8.96 to -2.67
SecondaryChange From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDRamipril 10 mg QD
Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-7.44 ± 0.764-8.20 ± 0.750-4.43 ± 0.773
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Ramipril 10 mg QD · ANCOVA · p = 0.006 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -3.01 · 95% CI -5.15 to -0.88
  • Azilsartan Medoxomil 80 mg QD vs Ramipril 10 mg QD · ANCOVA · p = <.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -3.77 · 95% CI -5.89 to -1.65
SecondaryChange From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDRamipril 10 mg QD
Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-15.60 ± 1.172-14.93 ± 1.151-6.73 ± 1.186
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Ramipril 10 mg QD · ANCOVA · p = <.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -8.87 · 95% CI -12.15 to -5.60
  • Azilsartan Medoxomil 80 mg QD vs Ramipril 10 mg QD · ANCOVA · p = <.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -8.20 · 95% CI -11.46 to -4.95
SecondaryChange From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean diastolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDRamipril 10 mg QD
Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-10.21 ± 0.898-9.85 ± 0.883-4.53 ± 0.909
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Ramipril 10 mg QD · ANCOVA · p = <.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -5.68 · 95% CI -8.19 to -3.17
  • Azilsartan Medoxomil 80 mg QD vs Ramipril 10 mg QD · ANCOVA · p = <.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented.) · Mean difference (final values): -5.32 · 95% CI -7.81 to -2.82

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Azilsartan Medoxomil 40 mg QD—8/294 (2.7%)22/294 (7.5%)
Azilsartan Medoxomil 80 mg QD—12/293 (4.1%)16/293 (5.5%)
Ramipril 10 mg QD—6/293 (2%)36/293 (12.3%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDRamipril 10 mg QD
Atrial fibrillationCardiac disorders1/2942/2931/293
Acute coronary syndromeCardiac disorders0/2940/2931/293
Angina pectorisCardiac disorders0/2941/2930/293
HydroceleCongenital, familial and genetic disorders0/2941/2930/293
Retinal detachmentEye disorders0/2941/2930/293
Salivary gland calculusGastrointestinal disorders0/2941/2930/293
AppendicitisInfections and infestations1/2940/2931/293
Hepatitis CInfections and infestations1/2940/2931/293
UrosepsisInfections and infestations1/2940/2931/293
Upper respiratory tract infectionInfections and infestations0/2941/2930/293
Most frequent other events
Most frequent other events
EventAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDRamipril 10 mg QD
CoughRespiratory, thoracic and mediastinal disorders3/2944/29324/293
NasopharyngitisInfections and infestations19/29413/29317/293

Baseline characteristics

Age, Customized
Age, Customized(Participants)Azilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDRamipril 10 mg QDTotal
<45 years404530115
Between 45 and 64 years166168195529
≥65 years898170240
Sex: Female, Male
Sex: Female, Male(Participants)Azilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDRamipril 10 mg QDTotal
Female136136149421
Male159158146463
09

Study locations

72 sites
  • Pleven, Bulgaria
  • Plovdiv, Bulgaria
  • Rouse, Bulgaria
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Paide, Estonia
  • Tallinn, Estonia
  • Tartu, Estonia
  • Viljandi, Estonia
  • Joensuu, Finland
  • Mikkeli, Finland
  • Tampere, Finland
  • Turku, Finland
  • Augsburg, Germany
  • Bad Krozingen, Germany
  • Bad Segeberg, Germany
  • Berlin, Germany
  • Dortmund, Germany
  • Dresden, Germany
  • Essen, Germany
  • Frankfurt, Germany
  • Goch, Germany
  • Grossheirath, Germany
  • Hamburg, Germany
  • Karlsruhe, Germany
  • Koeln, Germany
  • Kuenzing, Germany
  • Leipzig, Germany
  • Luebeck, Germany
  • Mannheim, Germany
  • Muenchen, Germany
  • Nuernberg, Germany
  • Siegen, Germany
  • Deurne, Netherlands
  • Ewijk, Netherlands
  • Geleen, Netherlands
  • Lichtenvoorde, Netherlands
  • Oude Pekela, Netherlands
  • Rijswijk, Netherlands
  • Roelofarendsveen, Netherlands
  • Rotterdam, Netherlands
  • Wildervank, Netherlands
  • Gdansk, Poland
  • Gniewkowo, Poland
  • Kamieniec Zabkowicki, Poland
  • Katowice, Poland
  • Libiaz, Poland
  • Lodz, Poland
  • Olawa, Poland
  • Plock, Poland
  • Poznan, Poland
  • Skierniewice, Poland
  • Tarnow, Poland
  • Moscow, Russian Federation
  • Perm, Russian Federation
  • St Petersburg, Russian Federation
  • Belgrade, Serbia
  • Niska Banja, Serbia
  • Nis, Serbia
  • Zemun, Serbia
  • Bratislava, Slovakia
  • Galanta, Slovakia
  • Levice, Slovakia
  • Lucenec, Slovakia
  • Rimavska Sobota, Slovakia
  • Boden, Sweden
  • Göteborg, Sweden
  • Luleå, Sweden
  • Lund, Sweden
  • Malmö, Sweden
  • Skene, Sweden
  • Örebro, Sweden
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2008
First posted
Sep 26, 2008
Start
Jan 2008
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results first posted
Apr 19, 2011
Last update
Nov 15, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00760214
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Sep 26, 2008
Start date
Jan 2008
Primary completion
Apr 2009
Completion
Apr 2009
Results posted
Apr 19, 2011
Last update
Nov 15, 2012

Study contacts

Medical Director
study director · Takeda Global Research & Development Center (Europe), Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azilsartan medoxomil

Start the discussion